-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
FEBRUARY 12, 2021 /--- According to a study published February 11 in the open-access journal PLOS Pathogen, in the majority of severe cases of COVID-19, most people can produce meso-antibodies against SARS-CoV-2.
study was conducted by Michael Mor of Tel Aviv University and colleagues.
, results support the prevention and treatment of COVID-19 using combination antibody therapy.
THE COVID-19 pandemic caused by SARS-CoV-2 has had a profound impact on global public health.
it is believed that neutral antibodies specific to the SARS-CoV-2 protrusion protein binding domain (RBD) are essential for controlling viruses.
RBD-specific neutral antibodies were detected in patients recovering from COVID-19.
some of the participants tended to have strong and long-lasting immunity, while others showed a decrease in the antibody.
, however, what factors affect effectiveness and the long-lasting antibody response remains unclear.
(Photo Source: Www.pixabay.com) To address this problem, Mor and colleagues used molecular and biometric techniques to compare B-cell responses in 8 patients with severe COVID-19 and 10 patients with mild symptoms in 1.5 months after infection.
patients with severe illness showed higher concentrations of RBD-specific antibodies and increased B-cell amplification.
of the 22 antibodies cloned from two of the patients, six showed effective mesosing against SARS-CoV-2.
bio-information analysis shows that in severe COVID-19 cases, most people will be able to easily produce meso-antibodies against SARS-CoV-2.
, the combination of different types of meso-antibodies completely prevents the spread of live viruses.
that these antibody mixtures could be further tested in clinical settings as a useful tool for preventing and treating COVID-19.
, the authors added: "Even if vaccines are available, it is important to provide special anti-SARS-CoV-2 therapies to health care providers.
and antibodies represent an effective and safe way to treat severe COVID-19 cases, especially in the elderly or chronically ill people who cannot easily produce these antibodies after infection or vaccination.
" (Bioon.com) Source: Most people are naturally armed against SARS-CoV-2: Study Original source: Mor M, Werbner M, Alter J, Safra M, Chomsky E, Lee JC, et al. (2021) Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors. PLoS Pathog 17(2): e1009165. doi.org/10.1371/journal.ppat.1009165